1. Clinical Overview of CJC-1295 with DAC
Molecule: CJC-1295 with Drug Affinity Complex (DAC) is a long-acting GHRH analog designed to stimulate the pituitary gland to increase endogenous growth hormone (GH) secretion and IGF-1 production.
Key Features:
- Long half-life (~6–8 days)
- Stable midnight GH surge restoration
- Minimal receptor desensitization
- Does not suppress endogenous GH production
- Promotes physiologic pulsatile GH release (unlike exogenous GH)
Primary Clinical Domains
- Recovery and repair
- Fat loss
- Lean mass preservation
- Sleep enhancement
- Cognitive support
- Hair, skin, and nail quality
- Anti-aging and longevity
2. Mechanisms of Action
2.1 Growth Hormone–Releasing Hormone (GHRH) Receptor Activation
CJC-1295 binds to GHRH receptors on pituitary somatotrophs, triggering:
- Increased GH synthesis & storage
- Enhanced GH pulse amplitude
- Improved IGF-1 formation in the liver
2.2 DAC (Drug Affinity Complex) Technology
The DAC component binds to plasma proteins (primarily albumin), dramatically extending half-life:
- Half-life: ~5–8 days vs minutes for native GHRH
- Weekly or twice-weekly dosing
- Stable GH/IGF-1 elevation
2.3 GH/IGF-1 Tissue-Level Benefits
Increases:
- Protein synthesis
- Collagen & extracellular matrix production
- Bone turnover & density
- Lipolysis & fat oxidation
- Muscle fiber repair
- Deep sleep architecture (especially slow-wave sleep)
2.4 Neurocognitive & Metabolic Effects
GH/IGF-1 axis enhances:
- Memory consolidation
- Insulin sensitivity
- Mitochondrial function
- Cellular repair pathways
3. Evidence Summary — Clinical Domains of Use
3.1 Fat Loss & Metabolic Improvement
GH improves:
- Visceral fat reduction
- Lipolysis during fasting
- Lean body mass retention
3.2 Muscle Recovery & Performance
Reported benefits:
- Faster connective tissue healing
- Enhanced muscle fiber repair
- Decreased DOMS
- Improved recovery windows
3.3 Sleep Quality
GH peaks during slow-wave sleep. Patients report:
- Deeper sleep
- Reduced nighttime awakenings
- Improved morning alertness
3.4 Skin, Hair & Aesthetic Outcomes
GH/IGF-1 enhances:
- Dermal thickness
- Collagen synthesis
- Hair quality
- Nail integrity
Frequently used in anti-aging aesthetic protocols.
3.5 Longevity & Healthy Aging
GH decline with age leads to sarcopenia, increased visceral fat, impaired sleep and cognition, and reduced tissue repair. CJC-1295 partially reverses this decline through physiologic GH restoration.
4. Clinical Protocols
4.1 Reconstitution
Add: 2 mL bacteriostatic saline → 2.5 mg/mL
or 1 mL saline → 5 mg/mL (more concentrated)
Gently roll, do not shake!
4.2 Administration
- Subcutaneous (abdomen, flank, outer thigh)
- Intramuscular also acceptable
4.3 Dosing Protocols
Standard Anti-Aging / Wellness
- 1–2 mg SC once weekly
Fat Loss / Metabolic Optimization
- 1 mg SC, 2× weekly (or 2 mg once weekly)
Performance & Recovery
- 2 mg SC once weekly or 1 mg SC twice weekly
Advanced Protocol / Severe GH Decline
- 2–2.5 mg SC twice weekly — Clinical discretion required.
4.4 Combination Therapy
CJC-1295 with DAC is commonly paired with:
- Ipamorelin (GH secretagogue)
- Tesamorelin (visceral fat)
- BPC-157 / TB-500 (injury/repair)
- AOD-9604 (fat loss)
- Epitalon (longevity)
4.5 Duration of Therapy
- 12–24 weeks typical, up to 1 year under supervision
- Many clinicians use quarterly cycling (12 weeks on / 4–6 weeks off)
5. Clinical Decision Trees
Decision Tree 1 — Candidate Evaluation
Age > 30 with symptoms of GH decline? → Yes
Poor sleep quality? → Yes
Low recovery capacity? → Yes
Visceral fat accumulation? → Yes
Contraindications? → Review
If ≥2 positive → CJC-1295 appropriate
Decision Tree 2 — Goal-Based Dosing
Fat loss → 1 mg twice weekly
Recovery → 2 mg weekly
Sleep optimization → 1 mg weekly
Anti-aging → 1–2 mg weekly
Athletic protocol → 2 mg weekly or split dosing
6. Safety & Contraindications
6.1 Contraindications
- Active malignancy
- Uncontrolled diabetes
- Severe cardiovascular disease
- Pregnancy / lactation
- Hypersensitivity
6.2 Adverse Effects (Dose-Dependent)
Usually mild:
- Water retention
- Tingling or numbness
- Mild joint stiffness
- Increased appetite
- Sleep intensity
Rare:
- Carpal tunnel-like symptoms
- Insulin sensitivity shifts (monitor in diabetics)
6.3 Monitoring Recommendations
- Fasting glucose / A1c
- IGF-1 (baseline and 6–8 weeks)
- Lipids
- Body composition
- Sleep quality
Legal Disclaimer
The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.
CJC-1295 with DAC, and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.
Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.
Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.
By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.
Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.
References — CJC-1295 with DAC Clinical Reference Guide
Provider Access Required
Create a provider account to read the full clinical guide for CJC-1295 with DAC.